Which has stronger valuation and earnings, ELOX or ACTU?

Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eloxx Pharmaceuticals N/A N/A -$5.99M -$1.54 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A

Is ELOX or ACTU more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Actuate Therapeutics N/A -346.19% -178.40%

Does the media prefer ELOX or ACTU?

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.61 beat Eloxx Pharmaceuticals' score of 0.45 indicating that Actuate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ATHE or ACTU?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$15.88M N/A N/A Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A

Is ATHE or ACTU more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Actuate Therapeutics N/A -346.19% -178.40%

Does the media favor ATHE or ACTU?

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 2 articles in the media. Alterity Therapeutics' average media sentiment score of 0.89 beat Actuate Therapeutics' score of 0.61 indicating that Alterity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ACTU or INCR?

Actuate Therapeutics presently has a consensus target price of $10.50, indicating a potential upside of 2,151.77%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ACTU or INCR?

InterCure has higher revenue and earnings than Actuate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A InterCure $78.47M 0.69 -$10.37M N/A N/A

Is ACTU or INCR more profitable?

InterCure's return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% InterCure N/A N/A N/A

Which has preferable earnings & valuation, ACTU or LONA?

Athira Pharma is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A Athira Pharma N/A N/A -$105.61M -$4.21 N/A

Is ACTU or LONA more profitable?

Actuate Therapeutics' return on equity of -346.19% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% Athira Pharma N/A -411.58% -225.73%

Which has preferable valuation and earnings, ACTU or ALDX?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A

Is ACTU or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -53.14% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% Aldeyra Therapeutics N/A -53.14% -34.94%

Actuate Therapeutics (ACTU) Competitors

$0.45 -0.02 (-4.14%)

As of 02:31 PM Eastern

Compare

ACTU vs. ELOX, ATHE, INCR, LONA, and ALDX

Should you buy Actuate Therapeutics stock or one of its competitors? Actuate Therapeutics's main competitors and comparable companies include Eloxx Pharmaceuticals (ELOX), Alterity Therapeutics (ATHE), InterCure (INCR), Athira Pharma (LONA), and Aldeyra Therapeutics (ALDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Actuate Therapeutics compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$5.99M	-$1.54	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.61 beat Eloxx Pharmaceuticals' score of 0.45 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eloxx Pharmaceuticals' return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Actuate Therapeutics	N/A	-346.19%	-178.40%

Eloxx Pharmaceuticals currently has a consensus target price of $38.33, suggesting a potential upside of 201.84%. Actuate Therapeutics has a consensus target price of $10.50, suggesting a potential upside of 2,151.77%. Given Actuate Therapeutics' higher possible upside, analysts plainly believe Actuate Therapeutics is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Eloxx Pharmaceuticals has a beta of -1960.42, suggesting that its stock price is 196,142% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Summary

Eloxx Pharmaceuticals beats Actuate Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Actuate Therapeutics compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Alterity Therapeutics' return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Actuate Therapeutics	N/A	-346.19%	-178.40%

2.1% of Alterity Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alterity Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Alterity Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 250.88%. Actuate Therapeutics has a consensus price target of $10.50, suggesting a potential upside of 2,151.77%. Given Actuate Therapeutics' higher possible upside, analysts plainly believe Actuate Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 2 articles in the media. Alterity Therapeutics' average media sentiment score of 0.89 beat Actuate Therapeutics' score of 0.61 indicating that Alterity Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alterity Therapeutics beats Actuate Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Actuate Therapeutics compare to InterCure?

Actuate Therapeutics (NASDAQ:ACTU) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Actuate Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, InterCure has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

InterCure has higher revenue and earnings than Actuate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
InterCure	$78.47M	0.69	-$10.37M	N/A	N/A

In the previous week, Actuate Therapeutics had 1 more articles in the media than InterCure. MarketBeat recorded 2 mentions for Actuate Therapeutics and 1 mentions for InterCure. InterCure's average media sentiment score of 1.82 beat Actuate Therapeutics' score of 0.61 indicating that InterCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
InterCure	Very Positive

8.3% of InterCure shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

InterCure's return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
InterCure	N/A	N/A	N/A

Actuate Therapeutics presently has a consensus target price of $10.50, indicating a potential upside of 2,151.77%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

InterCure beats Actuate Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Actuate Therapeutics compare to Athira Pharma?

Actuate Therapeutics (NASDAQ:ACTU) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

In the previous week, Actuate Therapeutics had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Actuate Therapeutics and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.82 beat Actuate Therapeutics' score of 0.61 indicating that Athira Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
Athira Pharma	Very Positive

57.1% of Athira Pharma shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 25.7% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Actuate Therapeutics presently has a consensus price target of $10.50, indicating a potential upside of 2,151.77%. Athira Pharma has a consensus price target of $17.33, indicating a potential upside of 169.57%. Given Actuate Therapeutics' higher possible upside, equities analysts plainly believe Actuate Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Actuate Therapeutics' return on equity of -346.19% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
Athira Pharma	N/A	-411.58%	-225.73%

Athira Pharma is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A

Actuate Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.11, suggesting that its share price is 111% more volatile than the broader market.

Summary

Actuate Therapeutics beats Athira Pharma on 7 of the 12 factors compared between the two stocks.

How does Actuate Therapeutics compare to Aldeyra Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aldeyra Therapeutics' return on equity of -53.14% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Actuate Therapeutics presently has a consensus target price of $10.50, suggesting a potential upside of 2,151.77%. Aldeyra Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 511.25%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Actuate Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

In the previous week, Actuate Therapeutics had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 2 mentions for Actuate Therapeutics and 1 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.82 beat Actuate Therapeutics' score of 0.61 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
Aldeyra Therapeutics	Very Positive

Summary

Actuate Therapeutics and Aldeyra Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Actuate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACTU vs. The Competition

Export

Metric	Actuate Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.78M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.51	807.81	275.40	25.37
Price / Sales	N/A	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	1.31	9.21	10.55	5.95
Net Income	-$22.23M	$2.84B	$3.50B	$380.75M
7 Day Performance	-38.41%	-4.00%	-3.92%	-3.96%
1 Month Performance	-56.70%	-8.07%	-8.30%	-6.81%
1 Year Performance	-94.49%	-5.86%	2.35%	-4.58%

Actuate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACTU Actuate Therapeutics	2.2095 of 5 stars	$0.45 -4.1%	$10.50 +2,249.0%	-94.2%	$10.78M	N/A	N/A	12	Gap Up
ELOX Eloxx Pharmaceuticals	2.8738 of 5 stars	$15.27 +0.9%	$38.33 +151.0%	+104,858.7%	$61.69M	$6.36M	N/A	7	News Coverage Gap Up
ATHE Alterity Therapeutics	3.2839 of 5 stars	$3.35 -0.6%	$10.00 +198.6%	-38.8%	$60.72M	N/A	N/A	11	Analyst Upgrade
INCR InterCure	0.9561 of 5 stars	$5.33 +0.1%	N/A	-39.1%	$58.26M	$78.47M	35.50	285	Positive News Gap Down
LONA Athira Pharma	3.7306 of 5 stars	$6.07 +5.6%	$17.33 +185.6%	N/A	$57.27M	N/A	N/A	19	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACTU) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actuate Therapeutics (ACTU) Competitors

ACTU vs. ELOX, ATHE, INCR, LONA, and ALDX

How does Actuate Therapeutics compare to Eloxx Pharmaceuticals?

Summary

How does Actuate Therapeutics compare to Alterity Therapeutics?

Summary

How does Actuate Therapeutics compare to InterCure?

Summary

How does Actuate Therapeutics compare to Athira Pharma?

Summary

How does Actuate Therapeutics compare to Aldeyra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actuate Therapeutics (ACTU) Competitors

ACTU vs. ELOX, ATHE, INCR, LONA, and ALDX

How does Actuate Therapeutics compare to Eloxx Pharmaceuticals?

Which has stronger valuation and earnings, ELOX or ACTU?

Does the media prefer ELOX or ACTU?

Is ELOX or ACTU more profitable?

Do analysts rate ELOX or ACTU?

Do institutionals and insiders hold more shares of ELOX or ACTU?

Which has more volatility & risk, ELOX or ACTU?

Summary

How does Actuate Therapeutics compare to Alterity Therapeutics?

Is ATHE or ACTU more profitable?

Do institutionals & insiders hold more shares of ATHE or ACTU?

Which has more volatility and risk, ATHE or ACTU?

Do analysts rate ATHE or ACTU?

Which has preferable earnings & valuation, ATHE or ACTU?

Does the media favor ATHE or ACTU?

Summary

How does Actuate Therapeutics compare to InterCure?

Which has more risk and volatility, ACTU or INCR?

Which has stronger valuation & earnings, ACTU or INCR?

Does the media prefer ACTU or INCR?

Do institutionals & insiders have more ownership in ACTU or INCR?

Is ACTU or INCR more profitable?

Do analysts recommend ACTU or INCR?

Summary

How does Actuate Therapeutics compare to Athira Pharma?

Does the media refer more to ACTU or LONA?

Do institutionals & insiders believe in ACTU or LONA?

Do analysts rate ACTU or LONA?

Is ACTU or LONA more profitable?

Which has preferable earnings & valuation, ACTU or LONA?

Which has more risk & volatility, ACTU or LONA?

Summary

How does Actuate Therapeutics compare to Aldeyra Therapeutics?

Do institutionals & insiders hold more shares of ACTU or ALDX?

Is ACTU or ALDX more profitable?

Which has preferable valuation and earnings, ACTU or ALDX?

Do analysts prefer ACTU or ALDX?

Which has more volatility & risk, ACTU or ALDX?

Does the media favor ACTU or ALDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools